ES2176354T3 - Uso de nebivolol como agente anti-aterogenico. - Google Patents

Uso de nebivolol como agente anti-aterogenico.

Info

Publication number
ES2176354T3
ES2176354T3 ES95942209T ES95942209T ES2176354T3 ES 2176354 T3 ES2176354 T3 ES 2176354T3 ES 95942209 T ES95942209 T ES 95942209T ES 95942209 T ES95942209 T ES 95942209T ES 2176354 T3 ES2176354 T3 ES 2176354T3
Authority
ES
Spain
Prior art keywords
aterogenic
nebivolol
agent
propensive
profilactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95942209T
Other languages
English (en)
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2176354T3 publication Critical patent/ES2176354T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UN DERIVADO DE {AL},{AL}'' IMINOBIS(METILEN)BIS[2 DICAMENTO PARA EL TRATAMIENTO TERAPEUTICO O PROFILACTICO DE PERSONAS QUE PADECEN O SON PROPENSAS A ENFERMEDADES DEGENERATIVAS Y TRASTORNOS DEL SISTEMA NERVIOSO Y VASCULAR ASOCIADAS AL ESTRES OXIDATIVO.
ES95942209T 1994-12-28 1995-12-21 Uso de nebivolol como agente anti-aterogenico. Expired - Lifetime ES2176354T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28

Publications (1)

Publication Number Publication Date
ES2176354T3 true ES2176354T3 (es) 2002-12-01

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95942209T Expired - Lifetime ES2176354T3 (es) 1994-12-28 1995-12-21 Uso de nebivolol como agente anti-aterogenico.

Country Status (20)

Country Link
US (2) US5874461A (es)
EP (1) EP0801564B1 (es)
JP (1) JPH10511655A (es)
KR (1) KR100264348B1 (es)
CN (1) CN1167418C (es)
AT (1) ATE214924T1 (es)
AU (1) AU700364B2 (es)
CA (1) CA2207333C (es)
CZ (1) CZ287513B6 (es)
DE (1) DE69526120T2 (es)
DK (1) DK0801564T3 (es)
ES (1) ES2176354T3 (es)
FI (1) FI118884B (es)
HU (1) HU226208B1 (es)
NO (1) NO315687B1 (es)
NZ (1) NZ298074A (es)
PT (1) PT801564E (es)
SI (1) SI0801564T1 (es)
SK (1) SK282144B6 (es)
WO (1) WO1996019987A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511655A (ja) * 1994-12-28 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗アテローム形成剤としてのネビボロールの使用
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
CA2446064A1 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
RU2378272C2 (ru) 2004-07-30 2010-01-10 Торрент Фармасьютикалз Лимитед Небиволол и его фармацевтически приемлемые соли, способ их получения и фармацевтические композиции небиволола
US20070014733A1 (en) * 2005-01-31 2007-01-18 O'donnell John P Hydroxylated nebivolol metabolites
PL2471530T3 (pl) 2005-06-01 2017-07-31 Edison Pharmaceuticals, Inc. Środki terapeutyczne o aktywności redoks do leczenia chorób mitochondrialnych i innych stanów oraz modulacja biomarkerów energetycznych
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
CA2736250C (en) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
AU2009327411A1 (en) * 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Feed supplement for mammalian cell culture and methods of use
ES2662051T3 (es) 2009-04-28 2018-04-05 Bioelectron Technology Corporation Tratamiento de neuropatía óptica hereditaria de Leber y atrofia óptica dominante con tocotrienol quinonas
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
ES2973279T3 (es) * 2014-10-24 2024-06-19 Launxp Biomedical Co Ltd Usos de medicamento de duloxetina·HCl en la preparación de una composición farmacéutica para el tratamiento de cáncer
WO2016100579A1 (en) 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
JP6905527B2 (ja) 2015-12-17 2021-07-21 ピーティーシー セラピューティクス， インコーポレイテッド 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JPH10511655A (ja) * 1994-12-28 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗アテローム形成剤としてのネビボロールの使用

Also Published As

Publication number Publication date
EP0801564A1 (en) 1997-10-22
CA2207333C (en) 2006-10-17
FI972793A0 (fi) 1997-06-27
SI0801564T1 (en) 2002-08-31
NZ298074A (en) 2001-01-26
DE69526120D1 (de) 2002-05-02
PT801564E (pt) 2002-09-30
WO1996019987A1 (en) 1996-07-04
HUT77927A (hu) 1998-11-30
CZ191997A3 (cs) 1999-01-13
KR100264348B1 (ko) 2000-08-16
US6075046A (en) 2000-06-13
CN1171739A (zh) 1998-01-28
SK85697A3 (en) 2000-04-10
DK0801564T3 (da) 2002-07-15
NO972980D0 (no) 1997-06-26
NO315687B1 (no) 2003-10-13
HU226208B1 (en) 2008-06-30
SK282144B6 (sk) 2001-11-06
CA2207333A1 (en) 1996-07-04
FI972793A (fi) 1997-06-27
US5874461A (en) 1999-02-23
DE69526120T2 (de) 2002-11-28
AU4347796A (en) 1996-07-19
CN1167418C (zh) 2004-09-22
AU700364B2 (en) 1999-01-07
MX9704669A (es) 1997-09-30
ATE214924T1 (de) 2002-04-15
CZ287513B6 (en) 2000-12-13
FI118884B (fi) 2008-04-30
JPH10511655A (ja) 1998-11-10
NO972980L (no) 1997-06-26
EP0801564B1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2157601T3 (es) Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
DE69905368T2 (de) Oxydiertes thymosin beta 4
MX9401807A (es) Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
BG101284A (en) Compounds and methods for cancer treatment
ES2078277T3 (es) Una nueva arginina desiminasa, su metodo de fabricacion y un agente anti-cancer que contiene esta enzima como un ingrediente eficaz.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
BR0010515A (pt) Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
ATE246929T1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
BR0009194A (pt) Composição do resorcinol
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
SV2002000355A (es) Aril- y heteroarilsulfonatos ref. lea 34321-sv
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ES2086526T3 (es) Aplicacion medicinal de m-csf.
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin